II.4 Efficacy, Effectiveness, and Immunogenicity. II.3 Vaccine Products Available for Use in Canada. Canadian Immunization Guide Chapter on Influenza: Clinical Information for Vaccine Providers I.1 New or Updated Information for 2019–2020. NACI members and liaison members conduct themselves within the context of PHAC’s Policy on Conflict of Interest, including yearly declaration of potential conflict of interest. Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). People administering the vaccine should also be aware of the contents of the relevant product monograph(s). PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. As NACI works towards full implementation of the expanded mandate, select Statements will include varying degrees of programmatic analyses for public health programs. Not all NACI Statements will require in-depth analyses of all programmatic factors. Over the coming years NACI will be refining methodological approaches to include these factors. 
The additional factors to be considered by NACI include: economics, ethics, equity, feasibility, and acceptability. In addition to burden of disease and vaccine characteristics, the Public Health Agency of Canada has expanded the mandate of NACI to include the consideration of programmatic factors in developing evidence-based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels. The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization. National Advisory Committee on Immunization (NACI) Preamble The trivalent formulation, Influvac ® (BGP Pharma ULC), is no longer available in Canada. Refer to the product monograph (PDF format) for further details.
Important notice: Influvac ® Tetra (BGP Pharma ULC, operating as Mylan EPD) quadrivalent inactivated influenza vaccine is now authorized by Health Canada for use in adults ≥18 years of age.
0 kommentar(er)
